MER-102 is in development for the treatment of deep vein thrombosis (DVT).
MER-102 is a unique tablet of an ultra low molecular weight heparin (uLMWH) made possible by Merrion's GIPET® technology.
All LMWH products are administered by injection and this limits the usefulness and market potential of these products. Nonetheless, the current market for these products as injectables is over $5 billion. Since LMWHs have the broadest safety margins of any anticoagulant therapy, the development of an oral dosage form would be of additional significant benefit to patients requiring long term prophylaxis for high risk of deep vein thrombosis, acute coronary syndrome, pulmonary embolism, and major orthopaedic surgery.
MER-102 has completed successful proof of concept trials.